Gilead Sciences, Inc. (GILD) Net Profit Margin: 30.99%
Is Gilead Sciences, Inc.’s net profit margin high or low?
Gilead Sciences, Inc.'s net profit margin of 30.99% is 103% above its 5-year average of 15.27%, near the high end of its 5-year range (0.50%–28.90%).
The net profit margin for Gilead Sciences, Inc. (GILD) is 30.99% as of Wednesday, June 10, 2026. It is above its 12-month average by 102.75% (15.29%).
GILD Net Profit Margin Chart
GILD Average Net Profit Margin Chart
GILD Current vs Average Net Profit Margin Chart
GILD Net Profit Margin Metrics
NET PROFIT MARGIN
30.99%
NET PROFIT MARGIN AVG TTM
15.29%
NET PROFIT MARGIN AVG 3Y
17.07%
NET PROFIT MARGIN AVG 5Y
15.27%
NET PROFIT MARGIN AVG 10Y
23.44%
NET PROFIT MARGIN AVG 15Y
26.91%
NET PROFIT MARGIN AVG 20Y
25.92%
CURRENT VS TTM AVG
+102.75%
CURRENT VS 3Y AVG
+81.52%
CURRENT VS 5Y AVG
+103.01%
CURRENT VS 10Y AVG
+32.19%
CURRENT VS 15Y AVG
+15.15%
CURRENT VS 20Y AVG
+19.57%
GILD Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | $151.21B | 30.99% | 15.29% | 17.07% | 15.27% |
| Abbott Laboratories (ABT) | $154.66B | 13.91% | 23.34% | 19.20% | 17.71% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 28.15% | 28.09% | 25.67% | 26.14% |
| Pfizer Inc. (PFE) | $146.36B | 11.83% | 12.51% | 14.97% | 18.18% |
| Danaher Corporation (DHR) | $130.25B | 14.89% | 15.52% | 19.51% | 19.37% |
| CVS Health Corporation (CVS) | $125.16B | 0.72% | 0.84% | 1.34% | 1.79% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 15.18% | 14.95% | 14.84% | 16.47% |
| Amgen Inc. (AMGN) | $183.75B | 20.95% | 16.61% | 20.49% | 22.20% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 15.01% | -1.95% | 6.91% | 3.59% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 35.40% | 13.94% | 25.44% | 29.40% |
Margin Comparison
Operating Margin
38.3%
Net Profit Margin
31.0%
Gilead Sciences, Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gilead Sciences, Inc. Net Profit Margin FAQ
- What is the net profit margin for Gilead Sciences, Inc. (GILD)?
- The net profit margin for GILD stock is 30.99%.
- Is Gilead Sciences, Inc.'s net profit margin high or low?
- Gilead Sciences, Inc.'s net profit margin of 30.99% is 103% above its 5-year average of 15.27%, near the high end of its 5-year range (0.50%–28.90%).
- What is the TTM average net profit margin for Gilead Sciences, Inc. (GILD)?
- The TTM average net profit margin for GILD stock is 15.29%.
- What is the 3Y average net profit margin for Gilead Sciences, Inc. (GILD)?
- The 3Y average net profit margin for GILD stock is 17.07%.
- What is the 5Y average net profit margin for Gilead Sciences, Inc. (GILD)?
- The 5Y average net profit margin for GILD stock is 15.27%.
- What is the 10Y average net profit margin for Gilead Sciences, Inc. (GILD)?
- The 10Y average net profit margin for GILD stock is 23.44%.
- What is the 15Y average net profit margin for Gilead Sciences, Inc. (GILD)?
- The 15Y average net profit margin for GILD stock is 26.91%.
- What is the 20Y average net profit margin for Gilead Sciences, Inc. (GILD)?
- The 20Y average net profit margin for GILD stock is 25.92%.
Gilead Sciences, Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 28.90% |
| 2024-12-31 | 1.67% |
| 2023-12-31 | 20.89% |
| 2022-12-31 | 16.83% |
| 2021-12-31 | 22.80% |
| 2020-12-31 | 0.50% |
| 2019-12-31 | 23.99% |
| 2018-12-31 | 24.65% |
| 2017-12-31 | 17.73% |
| 2016-12-31 | 44.43% |
| 2015-12-31 | 55.48% |
| 2014-12-31 | 48.62% |
| 2013-12-31 | 27.45% |
| 2012-12-31 | 26.72% |
| 2011-12-31 | 33.43% |
| 2010-12-31 | 36.50% |
| 2009-12-31 | 37.59% |
| 2008-12-31 | 37.09% |
| 2007-12-31 | 38.19% |
| 2006-12-31 | -39.32% |
| 2005-12-31 | 40.13% |
| 2004-12-31 | 33.92% |
| 2003-12-31 | -8.30% |
| 2002-12-31 | 15.45% |
| 2001-12-31 | 22.36% |
| 2000-12-31 | -29.03% |
| 1999-12-31 | -39.35% |
| 1998-12-31 | -29.65% |
| 1997-12-31 | -55.10% |
| 1996-12-31 | -64.97% |
Related Metrics
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day